Tags

Type your tag names separated by a space and hit enter

Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.
Cancer 2011; 117(16):3774-80C

Abstract

BACKGROUND

Palliative chemotherapy is aimed at increasing survival and palliating symptoms. However, the response rate to first-line chemotherapy in patients with nonsmall cell lung cancer (NSCLC) is less than 30%. Experimental studies have shown that supplementation with fish oil (FO) can increase chemotherapy efficacy without negatively affecting nontarget tissue. This study evaluated whether the combination of FO and chemotherapy (carboplatin with vinorelbine or gemcitabine) provided a benefit over standard of care (SOC) on response rate and clinical benefit from chemotherapy in patients with advanced NSCLC.

METHODS

Forty-six patients completed the study, n = 31 in the SOC group and n = 15 in the FO group (2.5 g EPA + DHA/day). Response to chemotherapy was determined by clinical examination and imaging. Response rate was defined as the sum of complete response plus partial response, and clinical benefit was defined as the sum of complete response, partial response, and stable disease divided by the number of patients. Toxicities were graded by a nurse before each chemotherapy cycle. Survival was calculated 1 year after study enrollment.

RESULTS

Patients in the FO group had an increased response rate and greater clinical benefit compared with the SOC group (60.0% vs 25.8%, P = .008; 80.0% vs 41.9%, P = .02, respectively). The incidence of dose-limiting toxicity did not differ between groups (P = .46). One-year survival tended to be greater in the FO group (60.0% vs 38.7%; P = .15).

CONCLUSIONS

Compared with SOC, supplementation with FO results in increased chemotherapy efficacy without affecting the toxicity profile and may contribute to increased survival.

Authors+Show Affiliations

Division of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21328326

Citation

Murphy, Rachel A., et al. "Supplementation With Fish Oil Increases First-line Chemotherapy Efficacy in Patients With Advanced Nonsmall Cell Lung Cancer." Cancer, vol. 117, no. 16, 2011, pp. 3774-80.
Murphy RA, Mourtzakis M, Chu QS, et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011;117(16):3774-80.
Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., Reiman, T., & Mazurak, V. C. (2011). Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer, 117(16), pp. 3774-80. doi:10.1002/cncr.25933.
Murphy RA, et al. Supplementation With Fish Oil Increases First-line Chemotherapy Efficacy in Patients With Advanced Nonsmall Cell Lung Cancer. Cancer. 2011 Aug 15;117(16):3774-80. PubMed PMID: 21328326.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. AU - Murphy,Rachel A, AU - Mourtzakis,Marina, AU - Chu,Quincy S C, AU - Baracos,Vickie E, AU - Reiman,Tony, AU - Mazurak,Vera C, Y1 - 2011/02/15/ PY - 2010/10/18/received PY - 2010/12/06/revised PY - 2010/12/21/accepted PY - 2011/2/18/entrez PY - 2011/2/18/pubmed PY - 2011/9/29/medline SP - 3774 EP - 80 JF - Cancer JO - Cancer VL - 117 IS - 16 N2 - BACKGROUND: Palliative chemotherapy is aimed at increasing survival and palliating symptoms. However, the response rate to first-line chemotherapy in patients with nonsmall cell lung cancer (NSCLC) is less than 30%. Experimental studies have shown that supplementation with fish oil (FO) can increase chemotherapy efficacy without negatively affecting nontarget tissue. This study evaluated whether the combination of FO and chemotherapy (carboplatin with vinorelbine or gemcitabine) provided a benefit over standard of care (SOC) on response rate and clinical benefit from chemotherapy in patients with advanced NSCLC. METHODS: Forty-six patients completed the study, n = 31 in the SOC group and n = 15 in the FO group (2.5 g EPA + DHA/day). Response to chemotherapy was determined by clinical examination and imaging. Response rate was defined as the sum of complete response plus partial response, and clinical benefit was defined as the sum of complete response, partial response, and stable disease divided by the number of patients. Toxicities were graded by a nurse before each chemotherapy cycle. Survival was calculated 1 year after study enrollment. RESULTS: Patients in the FO group had an increased response rate and greater clinical benefit compared with the SOC group (60.0% vs 25.8%, P = .008; 80.0% vs 41.9%, P = .02, respectively). The incidence of dose-limiting toxicity did not differ between groups (P = .46). One-year survival tended to be greater in the FO group (60.0% vs 38.7%; P = .15). CONCLUSIONS: Compared with SOC, supplementation with FO results in increased chemotherapy efficacy without affecting the toxicity profile and may contribute to increased survival. SN - 1097-0142 UR - https://www.unboundmedicine.com/medline/citation/21328326/Supplementation_with_fish_oil_increases_first_line_chemotherapy_efficacy_in_patients_with_advanced_nonsmall_cell_lung_cancer_ L2 - https://doi.org/10.1002/cncr.25933 DB - PRIME DP - Unbound Medicine ER -